ChurchRev. The story of the Odyssey. 3rd editionLondon: Seeley & Co., 1903; 128–9.
5.
CooperP. Poisoning. 3rd edition revised and enlarged. Solanine and Solanin SppLondon: Alchemist Publications, 1974;191–2.
6.
See reference 3, p.238.
7.
PlaitakisADuvoisinRC. Homer's Moly identified as Galanthus nivalis L: physiologic antidote to Stramonium poisoning. Clin Neuropharmacol1983; 6:1–5.
8.
HarborneJBaxterHMossG (ed.). Dictionary of plant toxinsChichester: John Wiley, 1996;167.
9.
See reference 8 p.240.
10.
HarveyAL. The pharmacology of galanthamine and its analogues. Pharmac Ther1995; 68:113–28.
11.
CozanitisDA. Experiences with galanthamine hydrobromide as curare antagonist. Der Anaesthesist1971; 20:226–9.
12.
AgarwalHCGuptaSE. Ocular hypotensive effect of galanthamine hydrobromide: an experimental study. Indian J Pharmacol1990; 22:117–8.
13.
BeightonPBeightonG. Alois Alzheimer. The man behind the syndromeBerlin and New York: Springer Verlag, 1986;8–9.
14.
AlzheimerA. Uber ein eigenartingen schweren Krankheitsprozess der einen Hirnrinde. Zentralbl. Nervenk1906; 25:1134.
15.
ThomsenTBickelUFischerJPKewitzH. Galanthamine hydrobromide in a long term treatment of Alzheimer's disease. Dementia 1. 1990;46–51.
16.
SummersWKMajovskiVMarshGM. Oral tetrahydroacridine in long term treatment of senile dementia, Alzheimer type. N Engl J Med1986; 315:1241–5.
17.
Drugs for dementia (Section 4.11) In: British national formulary, No. 35 British Medical Association and Royal Pharmaceutical Society of Great Britain, March 1998;232.
18.
RainerM. Clinical studies with Galanthamine. Drugs Today1997; 33:273–9.
19.
MorrisLCCyrusPAOrazemJ. Metrifonate benefits cognitive behavioural, and global function in patients with Alzheimer's disease. Neurology1998; 50:1222–30.
20.
LevyR. Effect of drugs can be variable in new drug treatment for Alzheimer's disease (letter). BMJ1998; 317:924.